State-of-the-art drug-eluting metal stents are the gold standard for interventional treatment of coronary artery disease.
with DES with either a bioresorbable polymer coating or a durable coating demonstrated a significantly lower rate of definite very late stent thrombosis with the bioresorbable polymer coating during a 4-year follow-up (8) . Additionally, improved vasomotion and endothelialization was seen (9, 10) , although hard endpoints (e.g., myocardial infarction, TLR, cardiac death) did not differ significantly (8, 11) . In another randomized, controlled trial, no significant differences were observed in outcomes between DES types during a 3-year follow-up (12) . Furthermore, a recent metaanalysis revealed nonsuperiority, even inferiority, of DES coated with bioresorbable polymer compared with cobalt-chromium everolimus-eluting stents (13) . In addition to the need for more long-term data, further challenges must be addressed to improve preliminary results. Nevertheless, this stent type cannot resolve long-term vessel caging and the side effects associated with permanent implants.
The next interventional cardiology advance may be the introduction of bioresorbable scaffolds (BRS). The term scaffold highlights the temporary nature of a BRS, distinct from a stent associated with a permanent implant. All resorbable scaffolds are commonly referred to as bioresorbable, even though some are not made of biomaterials.
The idea of dissolvable scaffolds is not new, dating to the description of Tamai et al. (14) of the first successful use of a fully degradable stent in the early 1990s. However, this concept was nearly forgotten due to the success of bare-metal stents and, later, DES. With long-term data and the revelation of the risks of metal stents, BRS development was reinitiated, resulting in a variety of devices.
MATERIAL COMPOSITION AND PROPERTIES
The optimal BRS should ensure adequate short-to mid-term scaffolding of the previously stenosed vessel to avoid recoil and completely dissolve afterward to prevent side effects. Thus, temporarily sufficient radial support is needed, with struts as thin as possible. The design should warrant deliverability and straightforward handling, flexibility in different anatomic circumstances, and integrity during resorption. The optimal duration until full resorption
is not yet defined. To achieve these goals, a consid- MAGNESIUM. Magnesium, complemented by rare earth metals to improve radial strength, is another currently used BRS production base. The first magnesium-based scaffolds were uncoated and lacked antiproliferative drug elution. The underlying idea is that the electronegative charge that emerges during the degradation of metal BRS is antithrombotic (16, 17) . A further potential benefit is its high mechanical strength, making it a stent with thinner struts, but radial strength similar to that of other bioresorbable scaffolds, possible. Depending on composition, degradation takes between 2 and 12 months.
The products of stent dissolution by corrosion are inorganic salts (17) . The latest generation device offers 9 to 12 months of radial support (18) .
OTHER MATERIALS
A tyrosine polycarbonate-based BRS providing up to 6 months of radial support is also under investigation.
Resorption takes between 24 and 36 months. Final products of degradation, which starts with hydrolysis and ends with the Krebs cycle, are ethanol, water, and carbon dioxide (19) .
A BRS made of polylactic anhydride containing 2 salicylic acid molecules linked to 1 sebacic acid Continued on the next page Wiebe et al.
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